장기 칩(OoC) 시장 : 유형, 제공, 기술, 장기 유형, 소재, 용도, 최종사용자별 - 시장 예측(2026-2032년)

The Organs-on-chips Market is projected to grow by USD 1,345.22 million at a CAGR of 30.12% by 2032.

The organs-on-chips market is advancing from a specialized research niche into a strategic platform for drug discovery, disease modeling, toxicity testing, and precision medicine. Also known as organ-on-chip technology or microphysiological systems, these devices combine living human cells, microfluidics, tissue engineering, sensors, and controlled mechanical cues to mimic key physiological functions of organs such as the liver, lung, heart, kidney, gut, skin, and brain.

Demand is being reinforced by a clear scientific and regulatory shift toward human-relevant, non-animal testing methods. The U.S. FDA Modernization Act 2.0, signed in 2022, removed the statutory requirement that investigational drugs be tested in animals before human trials, while agencies and standards bodies continue to evaluate new approach methodologies for regulatory use. For pharmaceutical, biotechnology, cosmetics, chemical, and academic stakeholders, organs-on-chips offer a data-rich path to improving translational predictability, reducing late-stage failures, and accelerating safer product development.

Transformative Shifts in the Organs-on-Chips Landscape

The landscape is being reshaped by the convergence of microfluidics, stem cell biology, 3D cell culture, biomaterials, and real-time analytics. Early organ-on-chip systems were often single-organ proof-of-concept platforms; the industry is now moving toward standardized, multi-organ, automated, and scalable systems that can support higher-throughput screening, longer-duration studies, and more physiologically relevant readouts.

A second major shift is the expanding role of regulators, consortia, and public research programs. The NIH Tissue Chip program, launched in 2012, helped validate the scientific foundation of microphysiological systems, while organizations such as the FDA, EMA, OECD, and national research agencies continue to assess how these models can complement or replace traditional in vivo and in vitro methods. This is pushing developers to improve reproducibility, assay validation, documentation, and compatibility with regulated workflows.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is becoming a force multiplier for organs-on-chips by improving experimental design, image analysis, signal interpretation, and predictive modeling. Organ-on-chip platforms generate high-content data from microscopy, biosensors, transcriptomics, proteomics, metabolomics, electrophysiology, and fluidic readouts; AI can integrate these complex datasets to identify toxicity signatures, disease phenotypes, and drug-response patterns faster than manual analysis.

The cumulative impact is especially important for pharmaceutical R&D, where AI-enabled microphysiological systems can support better candidate prioritization and mechanism-of-action analysis. Machine learning models trained on human-relevant chip data may help reduce reliance on animal models, strengthen in vitro-to-in vivo extrapolation, and enable digital twins for specific tissues or patient populations. However, industry adoption depends on transparent algorithms, high-quality training datasets, standardized metadata, and validation frameworks that regulators can review.

Key Regional Insights Across Organs-on-Chips Markets

North America remains a leading region for organs-on-chips because of its strong pharmaceutical R&D base, federal support for alternatives to animal testing, advanced university ecosystems, and active participation from regulatory science programs. The United States is particularly influential due to the presence of major biopharma research activity, microphysiological system development, and government-backed initiatives focused on translational safety assessment, while Canada strengthens the region through translational medicine and biotechnology research networks.

Europe is also a critical hub, supported by strong biomedical engineering capabilities, EU research funding, and policy momentum around replacement, reduction, and refinement of animal testing. The European Union's longstanding restrictions on animal testing for cosmetics continue to create demand for human-relevant in vitro models, while the United Kingdom, Germany, France, Italy, and Spain contribute through academic research, contract research capabilities, clinical networks, and biopharma partnerships.

Asia-Pacific is gaining momentum through fast-growing biopharmaceutical investment, regenerative medicine programs, and expanding academic output in China, Japan, South Korea, India, and Australia. Latin America is emerging more gradually, with Brazil and Mexico showing potential through toxicology, academic, pharmaceutical, and cross-border research collaborations. The Middle East is building long-term opportunity through biotechnology investment, genomics programs, and research hospitals in Gulf countries, while Africa remains at an earlier stage, with selected innovation hubs exploring biomedical research capacity, infectious disease modeling, and global health applications.

Key Group Insights for Organs-on-Chips Adoption

ASEAN is becoming relevant for organs-on-chips through its expanding biomedical manufacturing base, clinical research capacity, and government-backed life sciences strategies in countries such as Singapore, Malaysia, Thailand, and Indonesia. Singapore's established biomedical ecosystem provides a regional anchor for advanced in vitro models, while broader ASEAN demand is linked to pharmaceutical testing, academic collaboration, and lower-cost R&D services.

The GCC is building long-term potential through national health transformation programs, genomics initiatives, investment in research hospitals, and biotechnology clusters. The European Union remains one of the strongest policy-driven environments for organ-on-chip adoption because of its commitment to new approach methodologies, chemicals safety modernization, and animal-testing reduction. BRICS countries, led by China, India, and Brazil, are strengthening domestic capabilities in drug development, toxicology, and biomedical engineering, creating demand for scalable and cost-effective microphysiological systems.

G7 countries continue to shape adoption through regulatory science, biopharma research intensity, public health funding, and advanced research infrastructure, with the United States, Japan, Germany, the United Kingdom, France, Italy, and Canada all contributing to scientific validation and applied use cases. NATO countries are also relevant because defense-related biomedical research often prioritizes radiation exposure, chemical safety, trauma, infectious disease, and human performance models, all of which can benefit from organs-on-chips and human-relevant microphysiological systems.

Key Country Insights in Organs-on-Chips

The United States leads global adoption because of its deep pharmaceutical pipeline, strong venture funding environment, federal research programs, and regulatory movement toward alternative methods. Canada contributes through translational medicine, academic innovation, and biotechnology clusters, while Mexico is positioned for gradual growth through medical device manufacturing capabilities and cross-border life sciences collaboration. Brazil is the most important Latin American market, supported by university research, pharmaceutical demand, and toxicology applications.

In Europe, the United Kingdom, Germany, and France are central markets due to strong biopharma ecosystems, engineering expertise, public research funding, and active academic-industry partnerships. Italy and Spain add momentum through biomedical research, clinical networks, and European research collaborations. Russia maintains scientific capabilities in biotechnology and biomedical engineering, although adoption is influenced by geopolitical conditions, restricted international collaboration, and supply-chain constraints.

China is rapidly scaling organ-on-chip research as part of broader investment in biopharmaceutical innovation, precision medicine, and domestic drug development. India's opportunity is linked to its large pharmaceutical industry, contract research sector, and increasing interest in predictive toxicology. Japan is a mature market with strengths in robotics, regenerative medicine, induced pluripotent stem cell research, and high-quality instrumentation, while South Korea's advanced bioengineering, electronics, and semiconductor capabilities support platform development. Australia contributes through strong academic research, clinical translation, toxicology programs, and participation in international biomedical collaborations.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize validated use cases rather than positioning organs-on-chips as universal replacements for animal testing. The strongest near-term opportunities are in liver toxicity, cardiac safety, gut absorption, blood-brain barrier modeling, oncology, inflammation, infectious disease, nephrotoxicity, and patient-specific disease modeling, where human-relevant data can directly improve decision-making.

Organizations should invest in standardization, automation, quality management, and interoperability with laboratory information management systems. Strategic partnerships with regulators, pharmaceutical organizations, contract research providers, academic centers, and standards bodies can accelerate acceptance. Developers that demonstrate reproducibility, cost-effectiveness, workflow compatibility, transparent data packages, and clear translational value will be better positioned to win enterprise-level adoption.

Research Methodology for Organs-on-Chips Analysis

This executive summary is built from verified secondary research, regulatory analysis, scientific literature review, and market intelligence across pharmaceutical R&D, microphysiological systems, organ-on-chip technology, toxicology, and new approach methodologies. Sources considered include public regulatory updates, government program information, peer-reviewed scientific publications, standards activity, regional life sciences policy developments, and publicly available commercialization signals.

The research approach emphasizes triangulation across demand drivers, technology maturity, application areas, regional adoption patterns, and stakeholder behavior. Qualitative insights were evaluated against observable signals such as funding activity, regulatory modernization, academic output, biopharma partnerships, validation studies, and commercialization progress, ensuring a balanced and data-backed view of the organs-on-chips landscape without relying on market sizing or forecasting.

Conclusion: Future of Organs-on-Chips

Organs-on-chips are moving toward mainstream relevance as the life sciences industry seeks more predictive, ethical, and human-relevant models for drug development and safety assessment. The technology is not replacing every existing model immediately, but it is becoming an increasingly important layer in preclinical decision-making, especially when combined with AI, multi-omics, biosensors, and automated analytics.

The strongest opportunities are for organizations that can translate scientific sophistication into reliable, standardized, and regulator-ready workflows. As global stakeholders continue to invest in alternatives to animal testing and more precise biomedical models, organ-on-chip platforms are positioned to play a central role in the future of translational research, predictive toxicology, and precision medicine.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Organs-on-chips Market, by Type

• 7.1. Multi-Organ-on-Chip
• 7.2. Single-Organ-on-Chip
• 7.3. Dual-Organ-on-Chip

8. Organs-on-chips Market, by Offering

• 8.1. Instruments
  • 8.1.1. Culture Modules
  • 8.1.2. Controllers
  • 8.1.3. Incubator-Compatible Devices
• 8.2. Ready-To-Use Organ Models
• 8.3. Sensors / Readout Modules
• 8.4. Consumables
  • 8.4.1. Plates
  • 8.4.2. Reagents
  • 8.4.3. Chips
    • 8.4.3.1. Single Chips
    • 8.4.3.2. Multi-Chip Plates
• 8.5. Solutions
  • 8.5.1. Study Design Software
  • 8.5.2. Firmware Tools
• 8.6. Services
  • 8.6.1. CRO / Fee-For-Service Studies
  • 8.6.2. Assay Development
  • 8.6.3. Consulting & Training

9. Organs-on-chips Market, by Technology

• 9.1. Microfluidic Perfusion Systems
• 9.2. Passive Perfusion Systems
• 9.3. Gravity-Driven Perfusion
• 9.4. Pump-Driven Recirculating Perfusion

10. Organs-on-chips Market, by Organ Type

• 10.1. Gut
• 10.2. Heart
• 10.3. Kidney
• 10.4. Liver
• 10.5. Lung

11. Organs-on-chips Market, by Material

• 11.1. Glass-Based
• 11.2. PDMS-Based
• 11.3. Thermoplastic-Based

12. Organs-on-chips Market, by Application

• 12.1. Disease Modeling
• 12.2. Target Discovery
• 12.3. Personalized Medicine
• 12.4. Toxicology
• 12.5. Target Validation

13. Organs-on-chips Market, by End User

• 13.1. Pharmaceutical Companies
• 13.2. Biotechnology Companies
• 13.3. Contract Research Organizations
• 13.4. Academic & Research Institutes

14. Organs-on-chips Market, by Region

• 14.1. Asia-Pacific
• 14.2. North America
• 14.3. Latin America
• 14.4. Europe
• 14.5. Middle East
• 14.6. Africa

15. Organs-on-chips Market, by Group

• 15.1. ASEAN
• 15.2. GCC
• 15.3. European Union
• 15.4. BRICS
• 15.5. G7
• 15.6. NATO

16. Organs-on-chips Market, by Country

• 16.1. United States
• 16.2. Canada
• 16.3. Mexico
• 16.4. Brazil
• 16.5. United Kingdom
• 16.6. Germany
• 16.7. France
• 16.8. Russia
• 16.9. Italy
• 16.10. Spain
• 16.11. China
• 16.12. India
• 16.13. Japan
• 16.14. Australia
• 16.15. South Korea

17. Competitive Landscape

• 17.1. Market Concentration Analysis, 2025
  • 17.1.1. Concentration Ratio (CR)
  • 17.1.2. Herfindahl Hirschman Index (HHI)
• 17.2. Recent Developments & Impact Analysis, 2025
• 17.3. Product Portfolio Analysis, 2025
• 17.4. Benchmarking Analysis, 2025

18. Company Profiles

• 18.1. Emulate Inc.
• 18.2. CN Bio Innovations Ltd.
• 18.3. TissUse GmbH
• 18.4. MIMETAS B.V.
• 18.5. InSphero AG
• 18.6. Mattek by Sartorius AG
• 18.7. Sophion Bioscience A/S
• 18.8. Elvesys Group
• 18.9. Dynamic42 GmbH
• 18.10. BICO Group AB
• 18.11. Kirkstall Ltd.
• 18.12. NETRI SAS
• 18.13. Beonchip S. L.
• 18.14. AlveoliX AG
• 18.15. SynVivo Inc.
• 18.16. 4DCELL
• 18.17. AIM Biotech Pte. Ltd.
• 18.18. Altis Biosystems
• 18.19. Bi/ond Solutions B.V.
• 18.20. BiomimX S.r.l.
• 18.21. Cherry Biotech
• 18.22. Curi Bio
• 18.23. EDmicBio Inc.
• 18.24. Hesperos Inc.
• 18.25. Lena Biosciences
• 18.26. MEPSGEN Co., Ltd.
• 18.27. Obatala Sciences
• 18.28. Optics11 Life
• 18.29. Quris Technologies LTD.
• 18.30. React4life